Targeted therapeutics aim to treat diseases at the molecular level with precision and minimal side effects. Unlike traditional therapies that often affect healthy cells along with diseased ones, targeted therapeutics selectively act on specific molecules or pathways that are essential for disease progression. The knowledge of the molecular pathways underlying diseases is one of the pillars of targeted therapies. By identifying key molecules such as proteins, genes, or receptors involved in disease pathogenesis, researchers can develop drugs that specifically target these components.
A widely used targeted therapeutics is the use of monoclonal antibodies. These are laboratory-produced molecules that mimic the immune system’s ability to fight off harmful pathogens or abnormal cells. Through the use of genetic engineering, monoclonal antibodies can be made to recognize and attach to certain sites on cancer cells, obstructing their growth signals or designating them for immune system destruction. Another approach in targeted therapeutics involves small molecule inhibitors, which are drugs designed to interfere with specific biochemical pathways essential for disease progression. Antiviral drugs like protease inhibitors and polymerase inhibitors disrupt viral replication by targeting enzymes essential for viral proliferation.
Drugs like trastuzumab show remarkable success in treating various types of cancer, Imatinib for chronic myeloid leukemia and vemurafenib for melanoma are used as targeted therapies. Biologics, such as tumor necrosis factor (TNF) inhibitors and interleukin-6 (IL-6) provide relief for patients with conditions like rheumatoid arthritis and inflammatory bowel disease.
Currently, there are approximately 31 registered therapeutic monoclonal antibodies in the U.S. and Europe, with 160 undergoing clinical trials. Targeted therapies are part of a new approach known as personalized or precision medicine. Its use and significance is growing with time.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/targeted-therapeutics-market/
Global Targeted Therapeutics Market – Competitive Insights
Dec 2023 – Biomaterials-mediated targeted therapeutics of myocardial ischemia-reperfusion injury. Biomaterials are being developed to optimize the use of drugs by improving their targetability and bioavailability and reducing side effects of myocardial ischemia-reperfusion injury.
Oct 31, 2023 – Biotechnology company Vect-Horus has signed a global license agreement with Novo Nordisk for the development of targeted therapeutics.
Sep 25, 2023 – AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, has entered into a license agreement with Takeda to develop and commercialize AcuraStem’s PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Some of the Key Players in the Global Targeted Therapeutics Market Include –
- Roche
- Merck & Co., Inc.
- Novartis
- Bristol Myers Squibb (BMS)
- AstraZeneca
- Pfizer
- Amgen
- Gilead Sciences
- Johnson & Johnson
- AbbVie
Global Targeted Therapeutics Market – Growth Drivers
The growth of the targeted therapeutics market is driven by various factors be it from increasing molecular diseases to advanced medical technologies. Continuous advancements in molecular biology, genomics, and bioinformatics have provided deeper insights into the molecular mechanisms behind various diseases. This understanding enables the identification of novel therapeutic targets and the development of more precise targeted therapies tailored to specific molecular profiles of patients. The need for more efficient and targeted treatment choices is driven by the rising incidence of chronic diseases like cancer, heart disease, autoimmune diseases, and neurological disorders.
There is the evolution of various mutant species with time and changing environment. Many diseases, especially cancer, can develop resistance to traditional therapies over time, leading to treatment failure and disease progression. Targeted therapies can overcome or circumvent resistance mechanisms by directly targeting specific molecular vulnerabilities of cancer cells.
Global Targeted Therapeutics Market- Restraints
Targeted therapies typically target specific molecular pathways or genetic alterations, requiring a deep understanding of disease biology and molecular mechanisms. Developing drugs that selectively and effectively modulate these targets while minimizing off-target effects and toxicity can be challenging. The success of targeted therapies relies on the availability of reliable biomarkers thus in some diseases, suitable biomarkers may be scarce or inadequately validated, limiting patient stratification and hindering the widespread adoption of targeted therapies. Even though the goal of targeted therapy is to specifically inhibit disease-associated targets, off-target effects are still possible and can result in unintentional toxicity or negative reactions. The structural resemblance between the targeted molecule and other proteins may cause off-target effects, resulting in unexpected interactions.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/targeted-therapeutics-market/
Global Targeted Therapeutics Market – Opportunities
The shift towards personalized medicine emphasizes the importance of biomarker-driven therapies that target specific molecular alterations in individual patients. Oncology represents the largest segment of the targeted therapeutics market, driven by the growing incidence of cancer worldwide and the need for more effective and tolerable treatments. Targeted therapy drugs have been approved by the FDA to treat some types of cancer in 2023, including bladder, brain, breast, cervical, colorectal, dermatofibrosarcoma, and thyroid cancer. Advancements in drug delivery systems, such as nanoparticles and antibody-drug conjugates, enhance the efficacy and specificity of targeted treatments, opening up new market opportunities.
Global Targeted Therapeutics Market – Geographical Insights
The market for therapeutic medicines is segmented into regions such as North America, Latin America, Europe, Asia-Pacific, the Middle East, and Africa. North America holds a large targeted therapeutics market due to the high incidence of cancer in the region. As per the American Cancer Society, the number of new cancer cases in the U.S. stood at 1.95 million in 2023. According to Statistics Canada, there were 233,900 cases of cancer in 2022. The targeted therapeutics market is witnessing rapid global expansion, driven by increasing healthcare expenditure, improving access to healthcare services, and rising awareness of personalized medicine. Emerging markets in Asia-Pacific, Latin America, and the Middle East offer significant growth opportunities for pharmaceutical companies, with increasing demand for targeted therapies to address the burden of chronic diseases and infectious diseases in these regions.
Global Targeted Therapeutics Market – Key Development
- July 13, 2023 – The principle of targeting brain circuits has drawn increasing attention with the growth of brain stimulation treatments such as transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), and focused ultrasound (FUS).
- January 2022, next-generation CD47 blocker evorpacept, manufactured by ALX Oncology for treating patients with gastroesophageal junction and gastric cancer.